Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) closed the day trading at $32.61 up 1.34% from the previous closing price of $32.18. In other words, the price has increased by $1.34 from its previous closing price. On the day, 0.68 million shares were traded.
Ratios:
For a better understanding of HRMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.00 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.55. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.31. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Buy rating and assigned the stock a target price of $55.
On December 17, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $75.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 ’25 when JEFFREY G DIERKS bought 4,869 shares for $33.85 per share.
Dierks Jeffrey sold 13,125 shares of HRMY for $489,634 on Jan 24 ’25. The CHIEF COMMERCIAL OFFICER now owns 0 shares after completing the transaction at $37.31 per share. On Jan 27 ’25, another insider, Dierks Jeffrey, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 1,629 shares for $38.02 each. As a result, the insider received 61,941 and left with 0 shares of the company.
Valuation Measures:
As of this moment, Harmony’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.99, and their Forward P/E ratio for the next fiscal year is 8.21. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.62 while its Price-to-Book (P/B) ratio in mrq is 2.83.
Stock Price History:
Over the past 52 weeks, HRMY has reached a high of $41.61, while it has fallen to a 52-week low of $28.14. The 50-Day Moving Average of the stock is -10.26%, while the 200-Day Moving Average is calculated to be -5.18%.
Shares Statistics:
A total of 57.14M shares are outstanding, with a floating share count of 43.40M. Insiders hold about 24.31% of the company’s shares, while institutions hold 83.12% stake in the company.
Earnings Estimates
Harmony Biosciences Holdings Inc (HRMY) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $1.02, with high estimates of $1.18 and low estimates of $0.87.
Analysts are recommending an EPS of between $4.83 and $3.08 for the fiscal current year, implying an average EPS of $3.82. EPS for the following year is $5.05, with 3.0 analysts recommending between $5.81 and $4.4.
Revenue Estimates
8 analysts predict $183.76M in revenue for the current quarter. It ranges from a high estimate of $197.9M to a low estimate of $178.55M. As of the current estimate, Harmony Biosciences Holdings Inc’s year-ago sales were $154.62MFor the next quarter, 8 analysts are estimating revenue of $205.61M. There is a high estimate of $209.8M for the next quarter, whereas the lowest estimate is $201.51M.
A total of 9 analysts have provided revenue estimates for HRMY’s current fiscal year. The highest revenue estimate was $859.6M, while the lowest revenue estimate was $819.91M, resulting in an average revenue estimate of $842.4M. In the same quarter a year ago, actual revenue was $714.73MBased on 8 analysts’ estimates, the company’s revenue will be $991.25M in the next fiscal year. The high estimate is $1.05B and the low estimate is $933.77M.
